See more : Walker & Dunlop, Inc. (WD) Income Statement Analysis – Financial Results
Complete financial analysis of Microbix Biosystems Inc. (MBXBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Microbix Biosystems Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Royal Bank of Canada (RY) Income Statement Analysis – Financial Results
- BankInvest Mellemlange Danske Obligationaer (BAIMDOA.CO) Income Statement Analysis – Financial Results
- Ningbo Techmation Co.,Ltd. (603015.SS) Income Statement Analysis – Financial Results
- Smartvalue Co., Ltd. (9417.T) Income Statement Analysis – Financial Results
- China Finance, Inc. (CHFI) Income Statement Analysis – Financial Results
Microbix Biosystems Inc. (MBXBF)
About Microbix Biosystems Inc.
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.51M | 19.08M | 18.59M | 10.52M | 13.41M | 12.51M | 10.19M | 9.52M | 8.87M | 8.40M | 7.57M | 6.67M | 6.23M | 6.46M | 6.08M | 4.99M | 4.05M | 3.64M | 4.38M | 4.07M | 2.85M | 2.81M | 2.99M | 1.86M | 1.60M | 3.10M | 2.70M |
| Cost of Revenue | 9.03M | 7.95M | 7.55M | 5.86M | 6.86M | 7.14M | 5.37M | 4.54M | 3.03M | 3.89M | 3.74M | 3.91M | 3.24M | 2.73M | 2.52M | 2.48M | 2.12M | 1.75M | 1.68M | 1.49M | 1.02M | 835.27K | 949.84K | 577.27K | 600.00K | 600.00K | 500.00K |
| Gross Profit | 7.48M | 11.12M | 11.04M | 4.66M | 6.55M | 5.37M | 4.81M | 4.98M | 5.84M | 4.51M | 3.83M | 2.75M | 2.98M | 3.73M | 3.56M | 2.51M | 1.93M | 1.89M | 2.70M | 2.58M | 1.82M | 1.97M | 2.04M | 1.28M | 1.00M | 2.50M | 2.20M |
| Gross Profit Ratio | 45.30% | 58.32% | 59.40% | 44.28% | 48.82% | 42.92% | 47.25% | 52.33% | 65.81% | 53.73% | 50.62% | 41.30% | 47.92% | 57.78% | 58.60% | 50.36% | 47.74% | 51.94% | 61.72% | 63.36% | 64.03% | 70.24% | 68.22% | 68.91% | 62.50% | 80.65% | 81.48% |
| Research & Development | 2.05M | 1.80M | 1.03M | 1.01M | 1.04M | 1.09M | 994.58K | 493.61K | 1.28M | 691.07K | 445.82K | 560.00K | 530.07K | 494.25K | 703.06K | 1.19M | 985.42K | 886.05K | 572.87K | 966.80K | 668.39K | 443.78K | 346.67K | 228.62K | 3.80M | 1.60M | 900.00K |
| General & Administrative | 6.53M | 5.00M | 4.22M | 3.54M | 3.74M | 3.61M | 3.93M | 3.13M | 2.87M | 1.85M | 1.79M | 2.25M | 2.24M | 2.96M | 2.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.48M | 1.55M | 858.06K | 632.55K | 651.46K | 556.41K | 464.91K | 517.02K | 602.23K | 656.99K | 893.58K | 1.52M | 1.39M | 1.47M | 1.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.01M | 6.56M | 5.07M | 4.17M | 4.40M | 4.17M | 4.39M | 3.65M | 3.47M | 2.50M | 2.68M | 3.77M | 3.64M | 4.43M | 4.35M | 4.46M | 3.02M | 2.68M | 1.81M | 1.51M | 1.43M | 1.26M | 1.20M | 1.24M | 1.50M | 2.60M | 1.20M |
| Other Expenses | 161.24K | 160.34K | 99.40K | 0.00 | 0.00 | 0.00 | -273.54K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.22M | 8.51M | 6.21M | 5.19M | 5.44M | 5.26M | 5.39M | 4.14M | 4.75M | 3.19M | 3.09M | 4.33M | 4.63M | 5.39M | 5.93M | 6.00M | 4.27M | 3.81M | 2.55M | 2.63M | 2.25M | 1.86M | 1.73M | 1.67M | 5.60M | 4.50M | 2.30M |
| Cost & Expenses | 19.25M | 16.47M | 13.76M | 11.05M | 12.30M | 12.40M | 10.76M | 8.68M | 7.78M | 7.08M | 6.83M | 8.25M | 7.87M | 8.11M | 8.45M | 8.48M | 6.39M | 5.56M | 4.23M | 4.12M | 3.27M | 2.70M | 2.68M | 2.25M | 6.20M | 5.10M | 2.80M |
| Interest Income | 457.74K | 82.27K | 66.00 | 1.06M | 1.07M | 172.00 | 22.00 | 616.00 | 2.79K | 9.81K | 9.16K | 159.00 | 3.50K | 2.00K | 46.14K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 839.38K | 826.56K | 1.60M | 1.06M | 1.07M | 852.03K | 924.61K | 691.25K | 745.22K | 850.88K | 718.78K | 1.06M | 976.03K | 889.68K | 161.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.16M | 1.04M | 822.04K | 690.09K | 568.82K | 690.08K | 510.16K | 413.68K | 418.42K | 403.26K | 419.20K | 431.23K | 460.76K | 457.09K | 410.49K | 355.71K | 273.39K | 242.64K | 166.59K | 154.08K | 153.92K | 160.52K | 180.25K | 207.36K | 300.00K | 300.00K | 200.00K |
| EBITDA | 1.96M | 3.33M | 5.39M | -95.44K | 1.54M | -7.08M | -2.80M | 1.25M | 1.51M | 1.73M | 1.31M | -1.25M | -1.08M | -1.19M | -1.31M | -3.13M | -2.07M | -1.68M | 317.60K | 101.14K | -272.42K | 266.86K | 493.44K | -186.30K | -4.40M | -1.90M | 100.00K |
| EBITDA Ratio | 11.85% | 19.55% | 30.43% | 1.57% | 12.52% | 6.39% | -3.32% | 13.17% | 17.05% | 20.60% | 15.51% | -17.17% | -18.90% | -18.47% | -21.60% | -62.77% | -51.07% | -45.97% | 7.26% | 2.49% | -9.57% | 9.51% | 16.51% | -10.03% | -268.75% | -54.84% | 3.70% |
| Operating Income | -2.74M | 2.69M | 4.84M | -524.60K | 1.11M | -742.81K | -1.50M | 148.41K | 348.98K | 475.62K | 168.18K | -1.58M | -1.64M | -1.65M | -1.72M | -3.49M | -2.34M | -1.92M | 151.02K | -52.95K | -426.33K | 106.34K | 313.18K | -393.66K | -4.60M | -2.00M | -100.00K |
| Operating Income Ratio | -16.57% | 14.11% | 26.01% | -4.98% | 8.27% | -5.94% | -14.72% | 1.56% | 3.93% | 5.66% | 2.22% | -23.63% | -26.35% | -25.54% | -28.35% | -69.89% | -57.83% | -52.63% | 3.45% | -1.30% | -14.98% | 3.79% | 10.48% | -21.20% | -287.50% | -64.52% | -3.70% |
| Total Other Income/Expenses | 2.70M | -744.29K | -1.60M | -4.13M | -1.07M | -7.88M | -2.73M | -689.61K | -742.44K | -752.12K | 311.81K | -812.73K | -1.02M | -887.68K | 0.00 | 0.00 | -370.57K | -174.11K | 62.51K | 153.76K | 112.50K | 18.57K | 31.16K | 20.08K | 0.00 | 100.00K | 100.00K |
| Income Before Tax | -39.48K | 1.87M | 3.23M | -4.66M | 43.68K | -8.62M | -4.23M | 148.41K | 348.98K | 475.62K | 168.18K | -2.64M | -2.61M | -2.54M | 0.00 | 0.00 | -2.71M | -2.09M | 213.53K | 97.06K | -313.83K | 124.91K | 344.35K | -373.58K | 0.00 | -1.90M | 0.00 |
| Income Before Tax Ratio | -0.24% | 9.78% | 17.39% | -44.27% | 0.33% | -68.91% | -41.53% | 1.56% | 3.93% | 5.66% | 2.22% | -39.53% | -41.97% | -39.28% | 0.00% | 0.00% | -66.98% | -57.41% | 4.88% | 2.39% | -11.02% | 4.45% | 11.52% | -20.12% | 0.00% | -61.29% | 0.00% |
| Income Tax Expense | 0.00 | 77.23K | 1.60M | 1.57M | 11.76K | 852.03K | -450.00K | -600.00K | -265.00K | 306.65K | 166.80K | 159.00 | 3.50K | 887.68K | 759.98K | 177.83K | 0.00 | 211.61K | 88.00K | 82.79K | 49.88K | 55.40K | 103.23K | 76.65K | 100.00K | 200.00K | 100.00K |
| Net Income | -39.48K | 1.79M | 1.63M | -6.23M | 31.92K | -8.62M | -3.78M | 748.41K | 613.98K | 168.98K | 1.38K | -2.64M | -2.61M | -2.54M | -2.48M | -3.67M | -2.71M | -2.09M | 125.53K | 14.27K | -363.71K | 69.51K | 241.12K | -450.23K | -4.70M | -2.10M | -100.00K |
| Net Income Ratio | -0.24% | 9.38% | 8.77% | -59.17% | 0.24% | -68.91% | -37.11% | 7.86% | 6.92% | 2.01% | 0.02% | -39.53% | -41.97% | -39.28% | -40.85% | -73.45% | -66.98% | -57.41% | 2.87% | 0.35% | -12.78% | 2.48% | 8.07% | -24.25% | -293.75% | -67.74% | -3.70% |
| EPS | 0.00 | 0.01 | 0.01 | -0.06 | 0.00 | -0.09 | -0.04 | 0.01 | 0.01 | 0.00 | 0.00 | -0.04 | -0.05 | -0.05 | -0.05 | -0.08 | -0.07 | -0.06 | 0.00 | 0.00 | -0.01 | 0.00 | 0.01 | -0.01 | -0.14 | -0.06 | 0.00 |
| EPS Diluted | 0.00 | 0.01 | 0.01 | -0.06 | 0.00 | -0.09 | -0.04 | 0.01 | 0.01 | 0.00 | 0.00 | -0.04 | -0.05 | -0.05 | -0.05 | -0.08 | -0.07 | -0.06 | 0.00 | 0.00 | -0.01 | 0.00 | 0.01 | -0.01 | -0.14 | -0.06 | 0.00 |
| Weighted Avg Shares Out | 138.05M | 135.38M | 114.85M | 104.84M | 96.97M | 95.80M | 84.70M | 84.66M | 80.87M | 68.98M | 66.60M | 61.93M | 54.84M | 48.63M | 46.45M | 45.85M | 38.74M | 34.87M | 34.91M | 34.50M | 36.37M | 34.48M | 34.48M | 34.37M | 33.57M | 35.00M | 32.32M |
| Weighted Avg Shares Out (Dil) | 137.91M | 141.69M | 141.68M | 104.84M | 97.09M | 96.20M | 84.70M | 84.71M | 82.15M | 72.23M | 66.60M | 61.93M | 54.84M | 48.63M | 46.45M | 45.85M | 38.74M | 34.87M | 34.91M | 34.50M | 36.37M | 34.48M | 34.48M | 34.37M | 33.57M | 35.00M | 32.32M |
Microbix Unveils Test Control for Gastric Ulcer Disease Pathogen
MISSISSAUGA, Ontario, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces that it is presenting results of a Quality Assessment Product (“QAP™”) for supporting the clinical...
Microbix Biosystems Inc. (MBXBF) Q4 2023 Earnings Call Transcript
Microbix Biosystems Inc. (MBXBF) Q4 2023 Earnings Call Transcript
Microbix Achieves Further QAPs Sales Record
Over C$ 1 Million in One Shipment to a Leading Lab Accreditation Agency Over C$ 1 Million in One Shipment to a Leading Lab Accreditation Agency
Microbix Reports Results for Q4 & Full-Year Fiscal 2023
MISSISSAUGA, Ontario, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its year and fourth quarter ended September 30, 2023 (“2023” & “Q4”), with solid...
Microbix & Seegene USA Jointly Enhancing Lab Test Accuracy
Expanded Collaboration to Improve Syndromic Infectious Disease Testing Expanded Collaboration to Improve Syndromic Infectious Disease Testing
Microbix & BioGX Collaborate on real-time PCR Assays & Controls
Quality Controls for Respiratory Viral, Pharyngitis, and Genital Ulcer Disease Panels Quality Controls for Respiratory Viral, Pharyngitis, and Genital Ulcer Disease Panels
Microbix Announces Initiation of Normal Course Issuer Bid
MISSISSAUGA, Ontario, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces the initiation of a Normal Course Issuer Bid (“NCIB”) program for the repurchase and cancellation...
Microbix Presenting at Florida Capital Event Conference
MISSISSAUGA, Ontario, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting to investors at the Florida Capital Event Conference, organized by...
Microbix Clot-Buster Drug Fully-Funded For Return to U.S. Market
Sequel Pharma Reconfirms Kinlytic® urokinase Support for Catheter Clearance Indication Sequel Pharma Reconfirms Kinlytic® urokinase Support for Catheter Clearance Indication
Microbix & Ulisse Biomed Collaborate on HPV Controls & Assays
MISSISSAUGA, Ontario and TRIESTE, Italy, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces a collaboration with Ulisse Biomed S.p.A. (BIT: UBM, Ulisse), a company developing...
Source: https://incomestatements.info
Category: Stock Reports